News

Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer

Still basking in the glow of a likely advantageous deal it signed with the government the previous day, Pfizer's (NYSE: PFE) stock was extremely healthy on Hump Day. That positive sentiment was

Shares in Novo Nordisk (NYSE: NVO) were up 6% by 11:30 a.m. on Wednesday. The move comes after Pfizer's agreement with the Trump administration raised hopes that other pharmaceutical companies

Pfizer (NYSE: PFE) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. leadership in

If you were trying to find dividend stocks before the year 2000, the largest companies in the U.S. were a great place to look. Stalwarts like General Electric (today called GE Aerospace), Pfizer

Pfizer Inc (NYSE: PFE) closed at $25.48, rising 6.83%. Volume soared to over 153 million shares, nearly 3.5 times its three-month average of 43.3 million.

Indexes advanced modestly, led by

Pfizer (NYSE: PFE) stock was trading 3.6% higher as of 12:01 p.m. ET Tuesday after The Washington Post reported that the Trump administration had struck a deal with the pharmaceutical giant under

Pfizer (NYSE: PFE)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it. Even though it looks like cheap

It can be tough to invest in healthcare stocks. They're at the mercy of government programs that set reimbursement rates, they face political pressure on drug pricing and premiums, and they get

Investors seeking passive income sources that grow steadily have a few interesting options to choose from right now. Shares of Brookfield Infrastructure Corp. (NYSE: BIPC), Realty Income (NYSE: O)

It's been a rough few years to be a Pfizer (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine

Pfizer (NYSE: PFE) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and the average healthcare stock's yield of 1.7%. But Pfizer's lofty yield

The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader

In the pharmaceutical world, if you can't develop 'em, acquire 'em. That seems to be the philosophy behind Pfizer's (NYSE: PFE) latest big-ticket buy, specifically its purchase of clinical-stage

Want to invest in some low-priced stocks that possess a lot of upside in the long run? The stocks listed below could be great options for bargain hunters, as each one trades at less than $100 per

Remember Pfizer (NYSE: PFE), the giant pharmaceutical company that developed a COVID-19 vaccine within weeks of the pandemic hitting U.S. shores and got it approved within a year? It was the fastest

Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma giants Eli Lilly and Novo Nordisk dominate the market with their

The winds of political change have hit the healthcare industry, with drug makers seemingly taking the brunt of the gale. Industry-leading companies like Pfizer (NYSE: PFE), Merck (NYSE: MRK), and

The problem with trying to buy a stock at its low is that you'll only know whether it has bottomed out after it has done so. When it's in the midst of a sell-off, it's impossible to know how low

Pfizer (NYSE: PFE) is highly likely to survive the current headwinds it faces in the pharmaceutical sector. It has a long history and a strong core business. But it isn't the only drugmaker that's

A few years ago, Pfizer (NYSE: PFE) saw revenue soar to record heights thanks to coronavirus-related sales, from its vaccine Comirnaty and its treatment Paxlovid. On top of this, the company's

Shares of a little-known biotechnology stock called Metsera (NASDAQ: MTSR) popped on Monday, Sept. 22, after Pfizer (NYSE: PFE) announced it would be acquiring it for a steep premium. Under the

A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (NASDAQ: BNTX) shares higher as the stock trading week began on Monday. The Germany-based

Pfizer (NYSE: PFE), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug

The major market indexes are bumping against all-time highs. It's not surprising, therefore, that many stocks are trading at steep valuations. There are, however, some exceptions that are still